A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

被引：0
|
作者：
Takeo Fujii
Hiroko Masuda
Yee Chung Cheng
Fei Yang
Aysegul A. Sahin
Yasuto Naoi
Yuki Matsunaga
Akshara Raghavendra
Arup Kumar Sinha
Jose Rodrigo Espinosa Fernandez
Anjali James
Keisuke Yamagishi
Tomoko Matsushima
Robert Schuetz
Debu Tripathy
Sachiyo Tada
Rubie S. Jackson
Shinzaburo Noguchi
Seigo Nakamura
Jared D. Acoba
Naoto T. Ueno
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Breast Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354
[3] University of Hawai’i,John A. Burns School of Medicine
[4] University of Hawai’i Cancer Center,Department of Breast Surgical Oncology
[5] Showa University,Division of Hematology and Oncology
[6] Medical College of Wisconsin,Department of Translational Molecular Pathology
[7] The University of Texas MD Anderson Cancer Center,Department of Pathology
[8] The University of Texas MD Anderson Cancer Center,Department of Breast and Endocrine Surgery
[9] Osaka University Graduate School of Medicine,Anne Arundel Medical Center
[10] Sysmex Corporation,undefined
[11] Rebecca Fortney Breast Center,undefined
[12] Hyogo Prefectural Nishinomiya Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 189卷
关键词：
Breast cancer; 21-gene signature assay; 95-gene signature assay; Estrogen receptor-positive; Recurrence Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：455 / 461
页数：6
相关论文
共 50 条
  • [1] A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
    Fujii, Takeo
    Masuda, Hiroko
    Cheng, Yee Chung
    Yang, Fei
    Sahin, Aysegul A.
    Naoi, Yasuto
    Matsunaga, Yuki
    Raghavendra, Akshara
    Sinha, Arup Kumar
    Fernandez, Jose Rodrigo Espinosa
    James, Anjali
    Yamagishi, Keisuke
    Matsushima, Tomoko
    Schuetz, Robert
    Tripathy, Debu
    Tada, Sachiyo
    Jackson, Rubie S.
    Noguchi, Shinzaburo
    Nakamura, Seigo
    Acoba, Jared D.
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 455 - 461
  • [2] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Naoi, Yasuto
    Kishi, Kazuki
    Tsunashima, Ryo
    Shimazu, Kenzo
    Shimomura, Atsushi
    Maruyama, Naomi
    Shimoda, Masafumi
    Kagara, Naofumi
    Baba, Yosuke
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 299 - 306
  • [3] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Yasuto Naoi
    Kazuki Kishi
    Ryo Tsunashima
    Kenzo Shimazu
    Atsushi Shimomura
    Naomi Maruyama
    Masafumi Shimoda
    Naofumi Kagara
    Yosuke Baba
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2013, 140 : 299 - 306
  • [4] Development of recurrence risk score using 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative and node-negative breast cancer
    Naoi, Yasuto
    Saito, Yuria
    Kishi, Kazuki
    Shimoda, Masafumi
    Kagara, Naofumi
    Miyake, Tomohiro
    Tanei, Tomonori
    Shimazu, Kenzo
    Kim, Seung Jin
    Noguchi, Shinzaburo
    ONCOLOGY REPORTS, 2019, 42 (06) : 2680 - 2685
  • [5] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    Frontiers of Medicine, 2021, 15 : 621 - 628
  • [6] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Wu, Jiayi
    Gao, Weiqi
    Chen, Xiaosong
    Fei, Chunxiao
    Lin, Lin
    Chen, Weiguo
    Huang, Ou
    Zhu, Siji
    He, Jianrong
    Li, Yafen
    Zhu, Li
    Shen, Kunwei
    FRONTIERS OF MEDICINE, 2021, 15 (04) : 621 - 628
  • [7] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Ahn, Sung Gwe
    Cha, Yoon Jin
    Bae, Soon June
    Yoon, Chanik
    Lee, Hak Woo
    Jeong, Joon
    BMC CANCER, 2018, 18
  • [8] Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
    Jonathan Chen
    Xian Wu
    Paul J. Christos
    Silvia Formenti
    Himanshu Nagar
    Breast Cancer Research, 20
  • [9] Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
    Chen, Jonathan
    Wu, Xian
    Christos, Paul J.
    Formenti, Silvia
    Nagar, Himanshu
    BREAST CANCER RESEARCH, 2018, 20
  • [10] Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
    Sung Gwe Ahn
    Yoon Jin Cha
    Soon June Bae
    Chanik Yoon
    Hak Woo Lee
    Joon Jeong
    BMC Cancer, 18
12345